Results 51 to 60 of about 343,349 (228)

Quantitative Proteomics and CRISPR/Cas9 Editing Reveal UPR‐Mediated Control of Immunoglobulin Homeostasis in Hybridomas

open access: yesAdvanced Science, EarlyView.
BCR sequencing and subclone analysis correlated immunoglobulin (Ig) chain loss in dysfunctional hybridomas with disrupted monoclonal antibody homeostasis. Proteomics‐guided CRISPR/Cas9 editing revealed that the unfolded protein response (UPR) regulates aberrant Ig synthesis.
Rubing Zou   +9 more
wiley   +1 more source

Regulatory role of pro-Th1 and pro-Th2 cytokines in modulating the activity of Th1 and Th2 cells when B cell and macrophages are used as antigen presenting cells

open access: yesBMC Immunology, 2006
Background Presence of antigen presenting cells, expression of costimulatory molecules, the strength of first signal and cytokine milieu are quite important in influencing the reactivation of differentiated Th1 and Th2 cells. Results In the present study,
Agrewala Javed N, Singh Vinod
doaj   +1 more source

CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies

open access: yesFrontiers in Immunology, 2022
High-Grade Gliomas (HGG) are among the deadliest malignant tumors of central nervous system (CNS) in pediatrics. Despite aggressive multimodal treatment - including surgical resection, radiotherapy and chemotherapy - long-term prognosis of patients ...
Laura Antonucci   +5 more
doaj   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

open access: yesAdvanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong   +5 more
wiley   +1 more source

Immunocompetent murine models for the study of glioblastoma immunotherapy. [PDF]

open access: yes, 2014
Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in ...
Bloch, Orin   +9 more
core   +2 more sources

Expansion of Phenotypically Altered Dendritic Cell Populations in the Small Airways and Alveolar Parenchyma in Patients with Chronic Obstructive Pulmonary Disease

open access: yesJournal of Innate Immunity, 2022
Contrasting the antigen-presenting dendritic cells (DCs) in the conducting airways, the alveolar DC populations in human lungs have remained poorly investigated. Consequently, little is known about how alveolar DCs are altered in diseases such as chronic
Michiko Mori   +10 more
doaj   +1 more source

Core Fucosylation Represses SMURF1‐Dependent Degradation of CD47 to Promote Tumor Immune Evasion

open access: yesAdvanced Science, EarlyView.
FUT8‐mediated core fucosylation of CD47 at N111 blocks SMURF1 binding and reduces CD47 ubiquitination and degradation. Blocking N111 glycosylation reduces CD47 expression and promotes macrophage phagocytosis of tumor cells. Furthermore, ablating CD47 core fucosylation boosts CD103+ dendritic cells (DCs) infiltration, increases natural killer (NK) cell ...
Yuting Cao   +8 more
wiley   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

open access: yesAdvanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu   +11 more
wiley   +1 more source

Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial

open access: yesJournal for ImmunoTherapy of Cancer, 2021
Background Patients with recurrent glioblastoma (rGB) have a poor prognosis with a median overall survival (OS) of 30–39 weeks in prospective clinical trials.
Mark Kockx   +20 more
doaj   +1 more source

Early signaling defects in human T cells anergized by T cell presentation of autoantigen. [PDF]

open access: yes, 1992
Major histocompatibility complex class II-positive human T cell clones are nontraditional antigen-presenting cells (APCs) that are able to simultaneously present and respond to peptide or degraded antigen, but are unable to process intact protein ...
Freeman, GJ   +4 more
core  

Home - About - Disclaimer - Privacy